Cooper University Health Care is one of only 24 sites in the United States currently treating patients with central sleep apnea (CSA) with a new implantable device to stimulate breathing. The remedē® System, developed by medical technology company Respicardia, Inc., received FDA-approval in 2017 and is the first commercially available device to treat CSA.
“CSA is a serious breathing disorder that disrupts the normal breathing pattern during sleep and negatively affects quality of life and overall cardiovascular health,” said John A. Andriulli, DO, FACC, a clinical cardiologist at Cooper and director of the Arrhythmia Device Program at the Cooper Heart Institute. “It often occurs in cardiac patients, especially those with severe congestive heart failure, and is associated with a significantly greater risk for morbidity and mortality.”
At Cooper, a multidisciplinary team led by Dr. Andriulli along with Ramya Lotano, MD, FCCP, a pulmonologist and sleep expert, performed the first remedē® procedure in a patient with CSA.
CSA is different from the more commonly known obstructive sleep apnea, which is caused by upper airway obstruction. CSA results from the brain’s inability to send appropriate signals to the respiratory muscles to stimulate breathing. Treatment of the CSA patient is more challenging because the signal to the body to inhale is not being transmitted from the breathing center in the brain.
The remedē System is a pacemaker-like, battery-powered device that is placed under the skin in the upper chest area during a minimally invasive outpatient procedure by a cardiologist. The device has two small leads (wires): one that senses breathing, and one that stimulates the respiratory muscles to work when irregular breathing is detected.
“This new device is offering real hope to CSA patients who previously had very few options,” said Dr. Andriulli. “It can reduce the effects of CSA by improving sleep and, most importantly, the patient’s quality of life. Improved quality of sleep often leads to improvement in symptoms of heart disease and other medical problems.”
Cooper was the first hospital in the tristate area to implant this device following its FDA approval and is currently the only hospital in New Jersey to offer this treatment for CSA.
Wendy A. Marano
Public Relations Manager